Introduction
In some clinical settings such as deficiency of hormones, cytokines or clotting factors, long-term administration of proteins is mandatory. However, this type of therapy usually requires repeated intravenous or subcutaneous injection for months to years, which is stressful for the patients and the therapeutic compliance varies. Recently the feasibility of supplement gene therapy has been explored, in which genetically engineered cells are transplanted to secrete the desired proteins continuously.
At the termination of such a gene therapy or on occasions when the recombinant proteins exert undesired effects, the therapeutic genes should be shut down or the manipulated cells eradicated. To regulate transcription of the transgenes in cultured cells, several control means have been developed. Some of them involve inducible transcription systems such as metal-regulated promoters and tetracycline repressor (tetR), which allow reversible expression/repression of the transgenes. Considering their applications in vivo, however, these inducible systems have several limitations. Heavy metals are toxic and might not be tolerable for the subjects; tetR system requires continuous tetracycline administration to repress the target genes, which is sometimes problematic; other inducible systems have some leakiness and tight control is usually difficult to achieve. At present, transcriptional control of the transgene expression is still an underdeveloped technology and regulation of the secretory protein levels by producer cell elimination seems to be a more practical approach. For this purpose, 'suicide vectors' have been designed employing the herpes simplex virus 1 thymidine kinase (HSVtk) gene. 1, 2 This strategy is based on the fact that the viral enzyme converts barely toxic prodrugs such as ganciclovir (GCV) into highly toxic intermediates. Although the toxic metabolites should kill only the manipulated cells expressing HSVtk, this suicide system also has some limitations. For example, (1) the rate of cell killing is relatively slow; (2) nondividing cells are refractory, since this system depends on DNA synthesis to exert cytotoxicity; (3) GCV may cause nonspecific bone marrow suppression; (4) HSVtk is a foreign protein to the hosts and may evoke immunological reactions against the transduced cells.
As an alternative to the HSVtk/GCV system, a new strategy has recently been developed to eliminate the target cells. This system utilizes Fas-mediated apoptosis, controlled by the ligand-binding domain (LBD) of a nuclear receptor as a molecular switch. 3, 4 Fas (CD95; also referred to as APO-1), a membrane-bound protein, belongs to the tumor necrosis factor (TNF) receptor family and mediates apoptosis upon binding of Fas ligand (FasL) or cross-linking antibodies. [5] [6] [7] [8] [9] [10] When the transmembrane and cytoplasmic domains of Fas (Mfas) were fused with the LBD of the estrogen receptor (ER), estro-gen effectively induced apoptosis in L929 fibroblasts expressing the fusion protein (MfasER) both in vitro and in vivo. 4 In the present study, we examined whether this approach is a feasible way to control cytokine production at the cellular level. MfasER-mediated apoptosis should achieve prompt and extensive elimination of the target cells upon ligand treatment and has the potential for effective regulation of cytokine production. In addition, this strategy requires no special devices such as subcutaneous chambers to isolate the cytokine producers from the host's cellular immunity, or drastic procedures such as direct ethanol injection to eliminate the target cells.
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The simplicity of the cell elimination by the MfasER/ estrogen system would be another advantage in applications for supplement gene therapy.
Results
Establishment of L929 cells co-expressing MfasER and granulocyte colony-stimulating factor (G-CSF) MfasER, the fusion protein used in this study, is depicted in Figure 1 . The MfasER cDNA encodes the transmembrane through the cytoplasmic portion of the mouse Fas (amino acids 135-305) and the carboxyl-half of the rat ER (amino acids 286-600). 12, 13 The intracellular region of Fas contains a 'death domain' of some 70 amino acids, which plays a pivotal role in apoptotic signal transduction. 14 The carboxyl-half of ER contains the LBD and a ligandinduced dimerization motif of the nuclear receptor. 15 When L929 cells were transfected with an MfasER expression vector (pCMX/MfasER), they expressed a fusion protein with an apparent molecular weight of 57 kDa on Western blot analysis. 4, 16 The established subline of L929 expressing MfasER was designated as L929MfasER. L929MfasER cells were further transfected with a human G-CSF expression vector (pBCMGSNeo/GCSF), and the G418-resistant clones were titrated for G-CSF production. 17 The highest-titrated clone was designated as L929MfasERG. 
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TM (closed box), transmembrane region of Fas (amino acids 149-165); DD (hatched box), death domain of Fas (amino acids 201-286); DNA (dotted box), DNA-binding domain of ER (amino acids 185-267); LBD (shaded box), ligand-binding domain of ER (amino acids 286-600).
Estrogen-induced cell death of MfasER-expressing L929 cells At first, we examined the effects of estrogen on proliferating L929MfasERG cells. Figure 2 shows the morphological changes observed in L929MfasERG with 17␤-estradiol (E 2 ) treatment. After several hours with 10 −7 m E 2 , L929MfasERG became shrunken, showed cytoplasmic fragmentation and were detached from the culture dishes. The morphological alterations became more marked 12 h after E 2 treatment ( Figure 2C ), and most of the cells died within 24 h ( Figure 2E ). This apoptotic phenotype was identical to that observed in bona fide Fas-mediated cell death (Ref. 5 and unpublished observation). In contrast, 10 −7 m E 2 had no effect on the growth of parental L929 cells, which showed growth identical to that of the untreated cells (not shown).
To quantify the growth of the L929 cells expressing MfasER, we performed XTT assay on L929MfasER in the presence (10 −7 m) or absence of E 2 ( Figure 3) . 18 This assay is based on the fact that a tetrazolium reagent, 2,3-bis
, is metabolically reduced only in viable cells to form a water-soluble formazan product. Thus the formazan formation reflects the number of viable cells and is suitable for cell growth evaluation. As shown in Figure 3 , control L929 cells proliferated exponentially during the observation period (day −1 to day 3), regardless of the presence or absence of E 2 in the culture medium. Without E 2 stimulation, L929MfasER also continued to grow like the untransfected cells. However, addition of E 2 to the proliferating L929MfasER cells resulted in complete inhibition of cell growth and reduction of the viable cells. The XTT assay demonstrated extensive cell death of L929MfasER with estrogen, which was consistent with the morphological examinations ( Figure 2 ).
Apoptosis assays
To determine whether the estrogen-induced cell death of L929MfasERG was actually apoptosis, we performed two assays to detect DNA fragmentation and cytoplasmic nucleosomes, both of which are characteristic of apoptosis. After E 2 treatment, low molecular weight DNA was extracted from L929MfasERG cells and was subjected to 2% agarose gel electrophoresis. 19 DNA fragmentation was detected at as early as 30 min on E 2 treatment and became marked after 3-24 h (Figure 4a , lanes 3-6).
As the second apoptosis assay, we performed an enzyme-linked immunosorbent assay (ELISA) on E 2 -treated L929MfasERG. This assay (cell death detection ELISA) detects cytoplasmic nucleosomes with immobilized antihistone antibody-conjugated peroxidase. Figure  4b shows that the amount of cytoplasmic nucleosomes markedly increased in L929MfasERG cells after 2 h of E 2 incubation. With lower concentrations of E 2 such as 10
and 10 −7 m, cytoplasmic histones peaked at 5 h of incubation, whereas the amount of the liberated nucleosomes continued to increase for at least 9 h with 10 −6 m E 2 . These two assays confirmed that the estrogen-dependent cell death of L929MfasERG was apoptosis.
Estrogen-induced apoptosis in resting cells
Since the HSVtk/GCV suicide system depends on DNA synthesis in the target cells, nondividing cells are 
(A, B, D) L929MfasERG cells grew well without E 2 (A, 0 h; B, 12 h; D, 24 h). (C, E) L929MfasERG cells incubated with 10
−7 m E 2 . The E 2 -
treated cells markedly shrank and started to detach from the culture dishes after 12 h (C) and died within 24 h of incubation (E).
relatively resistant to the prodrug. On the other hand, Fas-mediated death signals are transmitted independently of DNA/RNA synthesis. We speculated that E 2 treatment would induce apoptosis in nondividing cells as effectively as in proliferating cells, and evaluated the cytocidal activity of HSVtk/GCV and MfasER/E 2 systems in resting cells.
L929 cells were transfected with an HSVtk expression vector (M2) and designated as L929TK. GCV or E 2 was added to L929TK or L929MfasER, respectively, when the cells were nearly confluent. As shown in Figure 5 , the viable cell numbers in the untreated populations almost plateaued during observation (day 0 to day 4), and we considered these cells to be mostly in the stationary phase. Likewise, most of L929TK and L929MfasER cells were presumably resting when challenged with GCV or E 2 , while these populations showed a striking difference in susceptibility ( Figure 5 ). That is, 10 −5 m GCV killed only 22% of L929TK in 96 h, showing the ineffectiveness of suicide induction in those cells by HSVtk/GCV. In contrast, 10 −7 m E 2 killed 95% of L929MfasER cells in 24 h. Taken together with the results shown in Figures 2 and 3 , we concluded that the MfasER/estrogen system worked effectively in both proliferating and resting cells.
G-CSF decrease with estrogen-induced apoptosis
We measured G-CSF production by L929MfasERG cells in the presence or absence of estrogen. Without estrogen, the amount of G-CSF released into the culture supernatant in 24 h increased with the proliferation of L929MfasERG cells (Figure 6 ). Upon E 2 treatment, G-CSF production decreased along with apoptosis of L929-MfasERG. After 2 days of E 2 treatment when very few
Figure 3 XTT assay of E 2 -treated L929 cells. Control L929 and L929MfasER cells were plated 24 h before E 2 treatment. E 2 (10 −7 m) was added to the culture media at time-point 0 and XTT assay was performed every 24 h during the observation period (day −1 to day 3). Closed squares, untreated L929 cells; open squares, E 2 -treated L929 cells; closed circles, untreated L929MfasER cells; open circles, E 2 -treated L929MfasER cells.
cytokine producers were alive, virtually no G-CSF was detected in the culture supernatant.
Discussion
Among several fusion constructs previously tested, apoptotic signals were transmitted by only those in which the transmembrane and cytoplasmic domains of Fas (Mfas) were fused to nuclear receptors. 4 Without the transmembrane domain, Fas-ER fusion protein did not induce apoptosis, probably because it failed to recruit the downstream proteins for death signal transduction. The precise mechanisms by which LBDs control the heterologous proteins in ligand-dependent ways remain to be clarified. As for intact Fas, the death signals are elicited upon trimerization of the receptor by trimeric FasL or multivalent cross-linking antibodies. Since the dimer formation of Fas by a bivalent antibody is not enough to induce apoptosis, 20 activation of MfasER by estrogen should involve (at least in part) mechanisms other than a simple hormone-induced dimerization. One possible explanation is that MfasER has some intrinsic capacity to multimerize or to form a death signaling complex particularly when overexpressed in a cell but these interactions may be blocked in an unliganded state. Binding of the appropriate ligand may liberate the fusion protein to form multimers or functional signal transducers. The involvement of heat-shock protein 90 (HSP90) with the nuclear receptors and a 'steric hindrance' model was pro- posed to explain how the LBD-fusion switching system works, although the extent to which this mechanism can be generalized is unclear. 3 In the present study, we evaluated the effectiveness and time course of estrogen treatment to induce apoptosis in genetically engineered L929 fibroblasts. The MfasER-expressing cells showed an apoptotic phenotype and died promptly and completely in response to E 2 treatment. In a previous study, the E 2 concentration required for apoptosis induction in the transfected L929 cells was 10 −10 m or higher, which well exceeds the physiological level of blood estrogen in female mice. 4 The MfasER-expressing cells, transplanted in nude mice, grew in vivo without interference by endogenous steroids. The implanted L929 cells showed an apoptotic phenotype only when estrogen was administered exogenously. Thus, the engineered cells homologous to L929MfasERG can survive and yield desired proteins in the recipient animals, and can still be eliminated by E 2 administration. An in vivo study to address this assumption is underway.
The advantage of the MfasER/E 2 system used in this study is its indifference to the cell cycle. E 2 induced apoptosis effectively whether the target cells were resting or proliferating, in contrast to the HSVtk/GCV system which showed only partial cytotoxicity in the resting cells. When this MfasER/estrogen system was applied to G-CSF producers, E 2 treatment rapidly killed the cytokine producers. Taken together, this apoptosis induction system may allow better control of the manipulated cells transplanted for cytokine gene therapy.
One of the limitations of this system is that it relies on the endogenous signal pathways downstream of Fas, involving FADD/MORT1 adaptor protein. 21 In addition, cells expressing a protein tyrosine phosphatase (FAP-1/PTP-BAS) are resistant to FasL killing. 22 Therefore, it is necessary to confirm the inducibility of Fas-mediated apoptosis in the target cells before applying the MfasER/estrogen strategy. In this context, another death signaling system, which involves TNF and TNF receptor I (TNFR-I), might be considered. Thus far, the TNFR-I-ER chimeric receptor has not yet been evaluated for the ability to control growth and apoptosis of the relevant cells. Further clarification of the apoptosis signaling pathways will lead to improvement in the present strategy and to the development of a more sophisticated means to regulate genetically manipulated cells.
Materials and methods
Plasmids
The cDNA encoding MfasER fusion protein was cloned into pCMX mammalian expression vector (from Dr K Umesono, Kyoto University, Kyoto, Japan) (pCMX/MfasER) to transfect L929 cells. 4, 16 The human G-CSF cDNA (from Dr S Nagata, Osaka University, Suita, Japan) was cloned into pBCMGSNeo (from Dr H Karasuyama, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan) (pBCMGSNeo/GCSF). 17, 23 pSV2bsr (from Kaken Pharma, Tokyo, Japan) is an expression vector harboring the blasticidin S-resistance gene (bsr). 24 M2 is a plasmid carrying the HSVtk gene. 25 Cells L929 mouse fibroblasts (from Dr M Hayakawa, Setsunan University, Osaka, Japan) were maintained in Dulbecco's modified minimum essential medium supplemented with 10% fetal calf serum (from Filtron, Brooklyn, Australia). 26 The fusion protein-expressing cells were established as follows. L929 cells were cotransfected with pCMX/MfasER and pSV2bsr plasmids by the calciumphosphate method. 27 After selection with 10 g/ml blasticidin S (Kaken Pharma), the resistant cells were cloned and MfasER-expressing cells were established (L929MfasER). L929MfasER cells were then transfected with pBCMGSNeo/GCSF and selected with 0.5 mg/ml G418 (Life Technologies, Grand Island, NY, USA). G418-resistant cells were cloned and evaluated for G-CSF production and the highest-titrated clone was selected (L929MfasERG). To establish HSVtk-expressing L929 cells, M2 plasmid was used for transfection. The transfectant cells obtained were termed L929TK.
Induction of growth inhibition and apoptosis
L929MfasERG cells were plated (1 × 10 6 cells per 100 mm dish) on the day before assay, and 10 −7 m E 2 (from Sigma, St Louis, MO, USA) was added to the early log-phase cultures. After designated periods of incubation with or without E 2 , L929MfasERG cells were examined on an inverted microscope and photographed (original magnification, × 400).
In parallel to the morphological examinations, XTT assay was performed on L929MfasER cells. 18 Cell Proliferation Kit II (XTT) (Boehringer Mannheim, Mannheim, Germany) was used to estimate the number of viable cells in the presence or absence of 10 −7 m E 2 , following the manufacturer's protocol.
To evaluate the cytotoxic activity of the suicide vectors in resting cells, L929TK and L929MfasER were plated (1 × 10 5 cells per 60 mm dish) and 10 −5 m GCV (Tanabe Pharmaceuticals, Osaka, Japan) or 10 −7 m E 2 was added to the culture the next day, when the cells were almost confluent. After designated periods of incubation, cells were trypsinized and the recovered viable cells were counted by the trypan blue exclusion method. The number of viable cells at each time-point was standardized, with the value for 0 h taken as 100%.
Detection of DNA fragmentation L929MfasERG cells were plated and E 2 was added to the culture on the following day as in morphological examinations. Low molecular weight DNA was extracted and electrophoresed on a 2% agarose gel to detect fragmented DNA. 19 In parallel, cytoplasmic histones in L929 cells, complexed with fragmented DNA, were quantified with Cell Death Detection ELISA kit (Boehringer Mannheim), following the manufacturer's protocol.
G-CSF production in genetically engineered fibroblasts On the day before E 2 treatment, 1 × 10 5 L929MfasERG cells were plated per 60 mm dish. The conditioned medium was collected just before E 2 treatment and every 24 h thereafter. Secreted G-CSF was quantified by ELISA. In parallel, positive control supernatant was harvested from the L929MfasERG cells without E 2 treatment.
